Publications and communications of Christine Gennigens

Van Nieuwenhuysen, E., Vergote, I., Randall, L. M., Tromp, J., Lorusso, D., O’Cearbhaill, R. E., Boere, I., Pisano, C., Sanchez, L. M., Banerjee, S., Collins, D. C., Zikán, M., Mathews, C., Kümmel, J., Melichar, B., Jackson, A. L., Madsen, K., Gennigens, C., Ottevanger, N., ... Monk, B. J. (April 2026). Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study. Gynecologic Oncology, 207, 3-13. doi:10.1016/j.ygyno.2026.02.008

Gilon, M., Boulet, D., Bours, V., Jerusalem, G., Josse, C.* , & Gennigens, C.*. (2026). Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies. Journal of Experimental and Clinical Cancer Research. doi:10.1186/s13046-026-03688-5

Baudin, L.* , Zanella, L.* , Lebeau, A., Pleyers, C., Gubbels, N., Blacher, S., Seidel, L., Kakkos, A., Goffin, F., Lovinfosse, P., Gennigens, C., Pirson, S., Kridelka, F.* , & Noël, A.*. (2026). Non-metastatic para-aortic lymph node remodeling as a predictor of outcome in locally advanced cervical cancer. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-25-3894

Streel, S., Kirkove, D., Gagnayre, R., Rorive, A., Freres, P., Gennigens, C., UCCELLO, S., Evrard, V., Greco, V., CAMPOS CORRAL, I., Seidel, L., Sibille, A., PAULUS, A., Pétré, B.* , & Jerusalem, G.*. (10 February 2026). Coping with checkpoint inhibitor adverse events: Assisting cancer patients in skills development - insights from the Immuno'Act© pre-experimental pilot study. Patient Education and Counseling, 147, 109537. doi:10.1016/j.pec.2026.109537

Van Nieuwenhuysen, E., Henry, S., Muylle, K., Demey, W., & Gennigens, C. (2026). Real-life data on clinical characteristics, treatments and outcomes of patients with newly diagnosed advanced-stage ovarian cancer: an observational study from Belgium. Acta Clinica Belgica, 1 - 11. doi:10.1080/17843286.2025.2608786

Banerjee, S. N., Van Nieuwenhuysen, E., Aghajanian, C., D'Hondt, V., Monk, B. J., Clamp, A., Prendergast, E., Oaknin, A., Ring, K., Colombo, N., Holloway, R. W., Rodrigues, M., Chon, H. S., Gourley, C., Santin, A. D., Thaker, P. H., Gennigens, C., Newman, G., Salinas, E., ... Grisham, R. N. (2025). The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201. Future Oncology. doi:10.1080/14796694.2025.2595130

Lebeau, A., Kakkos, A., LEROI, N., Bours, V., Delbecque, K., Goffin, F., Gonne, E., & Gennigens, C. (05 December 2025). Targeting synthetic lethality: an effective therapeutic approach in ovarian and endometrial cancers. Therapeutic Advances in Medical Oncology, 17, 17588359251392106. doi:10.1177/17588359251392106

Darimont, C., Pauwen, S., Fiona, M., LEBEAU, A., Seidel, L., Gonne, E., Goffin, F., Kakkos, A., Gennigens, C., & Kridelka, F. (November 2025). RISK FACTORS OF RECURRENCE IN EARLY-STAGE VULVAR CANCER (FIGO2021 I-II): INSIGHTS FROM A RETROSPECTIVE STUDY. International Journal of Gynecological Cancer, 35 (11), 102538. doi:10.1016/j.ijgc.2025.102538

LEBEAU, A., Pauwen, S., Darimont, C., Fiona, M., Seidel, L., Gonne, E., Goffin, F., Kakkos, A., Kridelka, F., & Gennigens, C. (November 2025). RECURRENCE IN ADVANCED VULVAR CANCER (FIGO III-IVA): CHARACTERISTICS ANALYSIS OF LOCAL AND DISTANT RELAPSES. International Journal of Gynecological Cancer, 35 (11), 102533. doi:10.1016/j.ijgc.2025.102533

Meuris, F., Darimont, C., Pauwen, S., LEBEAU, A., Kakkos, A., Goffin, F., Kridelka, F., Gennigens, C., Gonne, E., & Seidel, L. (November 2025). IMPACT OF STROMAL INVASION DEPTH ON RECURRENCE RISK IN EARLY (FIGO I–II) AND ADVANCED (FIGO III–IVA) STAGES VULVAR CANCER. International Journal of Gynecological Cancer, 35 (11), 102539. doi:10.1016/j.ijgc.2025.102539

Pauwen, S., LEBEAU, A., Fiona, M., Darimont, C., Seidel, L., Kridelka, F., & Gennigens, C. (November 2025). RADIATION THERAPY IN EARLY-STAGE VULVAR CANCER: A MONOCENTRIC RETROSPECTIVE STUDY. International Journal of Gynecological Cancer, 35 (11), 102534. doi:10.1016/j.ijgc.2025.102534

Wick, M., Streel, S., Gizzi, M., Seront, E., Sacre, A., Seidel, L., & Gennigens, C. (November 2025). Lymph node metastases and survival outcomes in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based therapies – A retrospective multicenter study. European Urology Open Science, 81, 297. doi:10.1016/s2666-1683(25)01672-6

Powell, M. A., Bjørge, L., Willmott, L., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., Gropp-Meier, M., Stuckey, A., Boere, I., Gold, M. A., Segev, Y., Gill, S. E., Gennigens, C., Sebastianelli, A., Shahin, M. S., Pothuri, B., ... Mirza, M. R. (09 September 2025). A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel. Therapeutic Advances in Medical Oncology, 17. doi:10.1177/17588359251342241

Blay, J.-Y., Teres Lleida, R., Martin-Broto, J., Caetano, C., De Haan, J. J., Debruyne, C., Desar, I., Duffaud, F., Gelderblom, H., Gennigens, C., Italiano, A., Jimenez Colomo, L., Lapeire, L., Mazzeo, F., Philip, J., Striefler, J. K., Svobodova, M., Tala, I., Valverde Morales, C. M., & Stacchiotti, S. (September 2025). 2749eP Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular pre-screening for IDH1 mutation in chondrosarcoma. Annals of Oncology, 36, 1460. doi:10.1016/j.annonc.2025.08.3359

Decruyenaere, A., Gennigens, C., Rottey, S., Laenen, A., Seront, E., Everaert, E., Debruyne, P. R., van den Bulck, H. F. M., Bastin, J., Verbiest, A. T. L., Vulsteke, C., Schatteman, P., Luyten, D., Aspeslagh, S., Martinez Chanza, N., De Bock, M. C. M., Meyskens, T. J., Verheezen, J., Brouwers, B., & Beuselinck, B. (September 2025). 2635P Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: Should we treat beyond two years? Annals of Oncology, 36, 1414-S1415. doi:10.1016/j.annonc.2025.08.3249

Monk, B. J., Van Nieuwenhuysen, E., Tromp, J., Lorusso, D., O'Cearbhaill, R. E., Banerjee, S., Collins, D. C., Zikan, M., Jackson, A. L., Madsen, K., Gennigens, C., Ottevanger, P. B., Ghamande, S., Salutari, V., Baurain, J.-F., Reyners, A., Conte, U., Windfeld, K., Hansen, H., & Vergote, I. (September 2025). 1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study. Annals of Oncology, 36, 769-S770. doi:10.1016/j.annonc.2025.08.1802

PETIT, E., Jerusalem, G., Denis, C., Wick, M., Freres, P., Gennigens, C., & Sautois, B. (September 2025). Les inhibiteurs de PARP (poly-ADP-ribose polymérase) : des nouveaux venus dans la prise en charge des cancers de la prostate. Revue Médicale de Liège, 80 (9), 592 - 597.

Decruyenaere, A., Gennigens, C., Sylvie, R., Annouschka, L., Seront, E., Everaert, E., Debruyne, P. R., Van Den Bulck, H., Bastin, J., Annelies, V., Vulsteke, C., Schatteman, P., Luyten, D., Aspeslagh, S., Martinez-Chanza, N., De Bock, M., Meyskens, T., Verheezen, J., Brouwers, B., & Beuselinck, B. (30 July 2025). Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years? Acta Oncologica, 64, 979 - 988. doi:10.2340/1651-226X.2025.43876

Banerjee, S. N., Van Nieuwenhuysen, E., Aghajanian, C., D'Hondt, V., Monk, B. J., Clamp, A., Prendergast, E., Oaknin, A., Ring, K., Colombo, N., Holloway, R. W., Rodrigues, M., Chon, H. S., Gourley, C., Santin, A. D., Thaker, P. H., Gennigens, C., Newman, G., Salinas, E., ... RAMP 201. (2025). Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. Journal of Clinical Oncology, 2500112. doi:10.1200/JCO-25-00112

Gennigens, C., & LEBEAU, A. (2025). Emerging therapies in gynaecological cancers (part 2): Endometrial cancer - Adjuvant and metastatic settings. Belgian Journal of Medical Oncology.

Gennigens, C., & LEBEAU, A. (May 2025). Emerging therapies in gynaecological cancers (part 1) : Locally advanced and metastatic cervical cancer. Belgian Journal of Medical Oncology, 19 (3), 88-95.

Neuberg, M., DECKER, E., Gennigens, C., Colin, G., Pottier, C., Lifrange, F., Kurth, W., & De Roover, A. (May 2025). La prise en charge du sarcome des tissus mous : du diagnostic au traitement. Revue Médicale de Liège, 80 (5-6), 330 - 333.

Wick, M., Denis, C., Freres, P., Sautois, B., Waltregny, D., & Gennigens, C. (May 2025). Prise en charge du cancer du rein en 2025. Revue Médicale de Liège, 80 (5-6), 323 - 329.

Dandoy, P., Gris, P.* , Radermecker, M., Gennigens, C., Wolter, P., & Sibille, A. (21 March 2025). Récidive tardive d'une tumeur fibreuse solitaire pulmonaire. Un sarcome "peu agressif", vraiment ? : présentation d'un cas clinique [Poster presentation]. 14ème Symposium de l'Association Francophone Belge d'Oncologie Thoracique, Namur, Belgium.

DHEUR, A., Kakkos, A., Danthine, D., Delbecque, K., Goffin, F., Gonne, E., Lovinfosse, P., Pleyers, C., THILLE, A., Kridelka, F., & Gennigens, C. (11 November 2024). Lymph node assessment in cervical cancer: current approaches. Frontiers in Oncology, 14. doi:10.3389/fonc.2024.1435532

Kuchimanchi, M., Jørgensen, T. L., Hanze, E., André, T., Jain, A., Berton, D., Alskär, O., Zub, O., Oaknin, A., Shahin, M. S., Koliadi, A., Pothuri, B., Krivak, T., Pishchyk, M., Segev, Y., Backes, F. J., Gennigens, C., Bouberhan, S., Zajic, S., ... Buscema, J. (2024). Population pharmacokinetics and exposure–response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY. British Journal of Clinical Pharmacology. doi:10.1111/bcp.16325

Gennigens, C., & LEBEAU, A. (05 September 2024). Highlights in gynaecological cancers. Belgian Journal of Medical Oncology, 18.

Salmon, A.* , LEBEAU, A.* , Streel, S., Dheur, A., Schoenen, S., Goffin, F., Gonne, E., Kridelka, F., Kakkos, A.* , & Gennigens, C.*. (22 June 2024). Locally advanced and metastatic endometrial cancer: Current and emerging therapies. Cancer Treatment Reviews, 129, 102790. doi:10.1016/j.ctrv.2024.102790

Powell, M. A., Bjørge, L., Willmott, L., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., Gropp-Meier, M., Stuckey, A., Boere, I., Gold, M. A., Segev, Y., Gill, S. E., Gennigens, C., Sebastianelli, A., Shahin, M. S., Pothuri, B., ... Mirza, M. R. (2024). Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial. Annals of Oncology. doi:10.1016/j.annonc.2024.05.546

Berton, D., Pautier, P., Lorusso, D., Gennigens, C., Gladieff, L., Kryzhanivska, A., Bowman, J., Tian, C., Cornfeld, M., & Van Gorp, T. (01 June 2024). Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study. Gynecologic Oncology, 186, 191 - 198. doi:10.1016/j.ygyno.2024.05.025

Mirza, M. R., Ghamande, S., Hanker, L. C., Black, D., Raaschou-Jensen, N., Gilbert, L., Oaknin, A., Secord, A. A., Savarese, A., Holloway, R. W., Kristeleit, R., Buscema, J., Boere, I. A., Sharma, S., Gennigens, C., Ghatage, P., Yablonski, K., Stevens, S., Trukhan, H., & Powell, M. A. (June 2024). 38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial. ESMO Open, 9, 103538. doi:10.1016/j.esmoop.2024.103538

Motzer, R. J., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Alekseev, B., Rha, S. Y., Merchan, J., Goh, J. C., Lalani, A.-K. A., De Giorgi, U., Melichar, B., Hong, S.-H., Gurney, H., Méndez-Vidal, M. J., Kopyltsov, E., Tjulandin, S., Gordoa, T. A., ... Gennigens, C. (Other coll.). (2024). Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology, 2301569. doi:10.1200/JCO.23.01569

Gennigens, C., De Ruyter, V., De Sutter, D., & Rottey, S. (2024). Prospective real-world experience with cabozantinib in patients with advanced renal cell carcinoma: Interim results of the Belgian REPLICA study. European Urology Open Science.

Gennigens, C., De Ruyter, V., De Sutter, D., & Rottey, S. (2024). Prospective real-world data confirm the tolerability of cabozantinib in patients with advanced renal cell carcinoma: Interim results of the Belgian REPLICA study. European Urology Open Science.

Vergote, I., Van Nieuwenhuysen, E., O'Cearbhaill, R. E., Westermann, A., Lorusso, D., Ghamande, S., Collins, D. C., Banerjee, S., Mathews, C. A., Gennigens, C., Cibula, D., Tewari, K. S., Madsen, K., Köse, F., Jackson, A. L., Boere, I. A., Scambia, G., Randall, L. M., Sadozye, A., ... Monk, B. J. (2023). Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Journal of Clinical Oncology, 2300720. doi:10.1200/JCO.23.00720

Lucia, F., Bourbonne, V., PLEYERS, C., Dupré, P.-F., Miranda, O., Visvikis, D., Pradier, O., Abgral, R., Mervoyer, A., Classe, J.-M., Rousseau, C., Vos, W., HERMESSE, J., Gennigens, C., De Cuypere, M., Kridelka, F., Schick, U., Hatt, M., Hustinx, R., & Lovinfosse, P. (2023). Multicentric development and evaluation of 18F-FDG PET/CT and MRI radiomics models to predict para-aortic lymph node involvement in locally advanced cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging. doi:10.1007/s00259-023-06180-w

Streel, S.* , Salmon, A.* , DHEUR, A., Bours, V., LEROI, N., Habran, L., Delbecque, K., Goffin, F., PLEYERS, C., Kakkos, A., Gonne, E., Seidel, L., Kridelka, F.* , & Gennigens, C.*. (02 March 2023). Diagnostic Performance of Immunohistochemistry Compared to Molecular Techniques for Microsatellite Instability and p53 Mutation Detection in Endometrial Cancer. International Journal of Molecular Sciences, 24 (5), 4866. doi:10.3390/ijms24054866

Hennuy, C., Defrère, P., MAWEJA, S., Thiry, A., & Gennigens, C. (November 2022). Bilateral breast desmoid - type fibromatosis, case report and literature review. Gland Surgery, 11 (11), 1832-1841. doi:10.21037/gs-22-271

Dheur, A., Bours, V., De Cuypere, M., Delbecque, K., Gennigens, C., Goffin, F., Gonne, E., HERMESSE, J., Kridelka, F., Lovinfosse, P., PLEYERS, C., Salmon, A., & Kakkos, A. (October 2022). 2022-RA-193-ESGO Cost-effectiveness of molecular profiling for endometrial neoplasia: a single institution experience [Poster presentation]. 23rd European Congress on Gynaecological Oncology. doi:10.1136/ijgc-2022-esgo.203

Salmon, A., Dheur, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kridelka, F., Kakkos, A., & Gennigens, C. (October 2022). Endometrial cancer: lymphovascular space invasion is a negative prognostic factor [Poster presentation]. 23rd European Congress on Gynaecological Oncology. doi:10.1136/ijgc-2022-esgo.264

DHEUR, A., Bours, V., De Cuypere, M., Delbecque, K., Gennigens, C., Goffin, F., Gonne, E., HERMESSE, J., Kakkos, A., Lovinfosse, P., PLEYERS, C., Salmon, A., & Kridelka, F. (29 September 2022). Defining prognostic risk groups amongst patients with endometrial cancer:respective role of 2009 figo stage and molecular profile [Poster presentation]. IGCS 2022, New York, United States.

Salmon, A., DHEUR, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kakkos, A., Kridelka, F., & Gennigens, C. (29 September 2022). Endometrial cancer: agreement between P53 immunohistochemistry and TP53 mutational analysis ? [Poster presentation]. IGCS 2022, New York, United States.

Gennigens, C., Jerusalem, G., LAPAILLE, L., De Cuypere, M., Streel, S., Kridelka, F., & Ray-Coquard, I. (09 September 2022). Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open, 7 (5), 1-3. doi:10.1016/j.esmoop.2022.100579

Mettlen, C., Gennigens, C., & Kurth, W. (2022). L’image du mois. Descellement aseptique d’une méga-prothèse de genou. Revue Médicale de Liège, 77 (1), 5-7.

ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., ... Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571

Vergote, I., Van Nieuwenhuysen, E., Casado, A., Laenen, A., Lorusso, D., Braicu, I., Guerra-Alia, E., Zola, P., Wimberger, P., Debruyne, P., Falco, E., Ferrero, A., Muallem, M., Kerger, J., Garcia Martinez, E., Pignata, S., Sehouli, J., Van Gorp, T., GENNIGENS, C., & Rubio Pérez, M. (12 October 2021). Randomised phase II BGOG/ENGOT-CX1 study of Paclitaxel-Carboplatin with or without Nintedanib in first-line recurrent or advanced cervical cancer [Paper presentation]. Int J Gynecol Cancer: first published as 10.1136/ijgc-2021-ESGO.16.

GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., KRIDELKA, F., & JERUSALEM, G. (2021). Optimal treatment in locally advanced cervical cancer. Expert Review of Anticancer Therapy, 657-671. doi:10.1080/14737140.2021.1879646

LAPAILLE, L., DE CUYPERE, M., GOFFIN, F., KAKKOS, A., GONNE, E., HERMESSE, J., LOVINFOSSE, P., DELBECQUE, K., THILLE, A., Kridelka, F., & GENNIGENS, C. (2021). Cancer du col utérin localement avancé : approche multidisciplinaire. Revue Médicale de Liège, 76 (5-6), 507-514.

Gennigens, C., DE CUYPERE, M., SEIDEL, L., HERMESSE, J., Barbeaux, A., Forget, F., Albert, A., Jerusalem, G., & Kridelka, F. (2020). Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. Cancer Medicine, 1-12. doi:10.1002/cam4.3465

FRERES, P., GENNIGENS, C., Martin, D., & Jerusalem, G. (October 2017). Leptomeningeal carcinomatosis from solid tumours : a systematic review of the literature. Belgian Journal of Medical Oncology, 11, 259-264.

GONNE, E., COLLIGNON, J., JERUSALEM, G., & GENNIGENS, C. (2016). Le carcinome de site primitif inconnu, une entité pas si rare. Revue Médicale de Liège, 71 (10), 449-454.

Crevecoeur, J., Jossa, V., GENNIGENS, C., Parmentier, J.-C., & Crevecoeur, A. (2015). Primary osteosarcoma of the breast : a case report. Clinical Case Reports. doi:10.1002/ccr3.450

FRERES, P., GONNE, E., COLLIGNON, J., GIOT, J.-B., GENNIGENS, C., & JERUSALEM, G. (2015). Prise en charge de la neutropénie fébrile chez le patient cancéreux. Revue Médicale de Liège, 70 (4), 195-200.

BARTHELEMY, N., GENNIGENS, C., Scholtes, F., TSHIBANDA, L., OTTO, B., PIRET, P., MARTIN, D., JERUSALEM, G., & COUCKE, P. (2014). Le traitement multidisciplinaire du glioblastome. Revue Médicale de Liège, 69, 63-68.

Benoit, A., Jerusalem, G., & GENNIGENS, C. (2013). Le cas clinique du mois. Métastase musculaire en présence d'un cancer de l'ovaire. Revue Médicale de Liège, 68 (11), 557-61.

Sautois, B., & GENNIGENS, C. (2013). Actualites therapeutiques dans le traitement medical du cancer de la prostate resistant a la castration. Revue Médicale de Liège, 68 (2), 94-6.

Marchal, N., GENNIGENS, C., & JERUSALEM, G. (November 2012). Carcinomatose péritonéale d'origine indéterminée. Revue Médicale de Liège, 67 (11), 582-586.

van der Graaf, W., Blay, J., Chawla, S., Kim, D., Bui-Nguyen, B., Casali, P., Schöffski, P., Aglietta, M., Staddon, A., Beppu, Y., Le Cesne, A., Gelderblom, H., Judson, I., Araki, N., Ouali, M., Marreaud, S., Hodge, R., Dewji, M., Coens, C., ... GENNIGENS, C. (19 May 2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 379 (9829), 1879-1886. doi:10.1016/S0140-6736(12)60651-5

BARTHELEMY, N., JANSEN, N., GENNIGENS, C., DELGAUDINE, M., & COUCKE, P. (2012). y a-t-il une place pour la radiothérapie en fin de vie ? Revue Médicale de Liège, 67 (3), 128/132.

GENNIGENS, C., & JERUSALEM, G. (2012). Pazopanib (Votrient) dans le traitement du cancer du rein et des sarcomes des tissus mous. Revue Médicale de Liège, 67 (7-8), 437-42.

GENNIGENS, C., & Jerusalem, G. (2011). Trabectedine (ET-743/Yondelis) dans le traitement des sarcomes des tissus mous et du cancer de l'ovaire. Revue Médicale de Liège, 66 (7-8), 452-5.

Freres, P., Collignon, J., Gennigens, C., Scagnol, I., Rorive, A., Barbeaux, A., Coucke, P., & Jerusalem, G. (March 2010). Le cancer du sein "triple négatif". Revue Médicale de Liège, 65 (3), 120-126.

Gennigens, C., Sautois, B., & Jerusalem, G. (2010). Le medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein métastatique. Revue Médicale de Liège, 65 (4), 212-6.

Collignon, J., Gennigens, C., Rorive, A., Coucke, P., Lifrange, E., Maweja, S., Fillet, G., & Jerusalem, G. (May 2009). ANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques. Revue Médicale de Liège, 64 (5-6), 279-83.

Gennigens, C., Collignon, J., Jerusalem, G., Rorive, A., & Sautois, B. (2009). Anticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites. Revue Médicale de Liège, 64 (5-6), 264-7.

GONNE, E., Collignon, J., Kurth, W., Thiry, A., Henry, F., Jerusalem, G., & Gennigens, C. (2009). Angiosarcome sur lymphoedeme chronique: un cas de syndrome de Stewart-Treves. Revue Médicale de Liège, 64 (7-8), 409-13.

Mievis, C., Jansen, N., Schleich, F., Gennigens, C., Rorive, A., Jerusalem, G., Fillet, G., & Sautois, B. (2009). Le cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide. Revue Médicale de Liège, 64 (4), 179-81.

PHAN BA, R., DEPRETER, M., GENNIGENS, C., LENELLE, L., PITANCE, F., MASSION, P., & CANIVET, J.-L. (2009). L'image du mois: Thrombus artériel pulmonaire proximal en échocardiographie. Revue Médicale de Liège, 64 (1), 4-5.

Paulus, A., Gennigens, C., Fillet, G., Loly, C., & Sautois, B. (September 2007). Traitement chimiothérapique actuel du cancer de l'ovaire. Revue Médicale de Liège, 62 (9), 539-47.

Gennigens, C., Sautois, B., Rorive, A., Fillet, G., & Jerusalem, G. (2007). Actualites therapeutiques en oncologie: l'essor des therapeutiques ciblees. Revue Médicale de Liège, 62 (5-6, May-Jun), 391-8.

Jerusalem, G., Rorive, A., Gennigens, C., Sautois, B., Mievis, C., & Fillet, G. (2007). Actualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles. Revue Médicale de Liège, 62 Spec No, 2-5.

Gillain, S., Gennigens, C., Sautois, B., Polus, M., Bonnet, C., Fillet, G., & Jerusalem, G. (2004). Traitement du cancer du sein chez la personne âgée. Revue Médicale Suisse, 62, 1618-21.

Frere, P., Canivet, J.-L., Gennigens, C., Rebeix, J. P., Fillet, G., & Beguin, Y. (2000). Hyperammonemia after high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplantation, 26 (3), 343-5. doi:10.1038/sj.bmt.1702485